Human Longevity, Inc. Appoints William A. Roper, Jr. as Chief Financial Officer
(SAN DIEGO, CA) September 28, 2015—Human Longevity, Inc. (HLI), the genomics-based, technology-driven company, an...
Human Longevity, Inc. and Discovery Ltd to Offer Whole Exome, Whole Genome and Cancer Genome Sequencing to Discovery Insurance Clients in South Africa and the United Kingdom
HLI Introduces a Whole Exome Sequencing Product for $250 USD (SAN DIEGO, CA and SANDTON, SOUTH AFRICA)—September...
Using the combined power of our core areas of expertise—genomics, informatics, and stem cell therapies, we are tackling one of the greatest medical/scientific and societal challenges—aging and aging related diseases. –Dr. J. Craig Venter
The global market for healthy human longevity is enormous with total healthcare expenditures in those 65 and older running well over $7 trillion. We believe that HLI’s unique science and technology, along with our business leadership, will positively impact the healthcare market with novel diagnostics and therapeutics. –Dr. Robert Hariri
HLI is going to change the way medicine is practiced by helping to shift to a more preventive, genomic-based medicine model which we believe will lower healthcare costs. Our goal is not necessarily lengthening life, but extending a healthier, high performing, more productive life span. –Dr. J. Craig Venter
Between 1910 and 2010 improvements in medicine and sanitation increased the human lifespan by 50 percent from 50 to 75 years. Today with the emergence of exponential technologies such as those being pioneered and advanced by HLI we have the potential to meaningfully extend the lifespan even further. –Dr. Peter H. Diamandis